In all 200 suffers were recruited to the trial and all of them have now past the three month stage.
A total of 46 patients, or just under a quarter, have completed the year-long assessment, while 40% have passed nine-months.
ImmuPharma said it remains on track to provide top-line results in the first quarter of next year.
The data was provided ahead of an investor update to be held in London that will be coupled with the company’s annual meeting later Friday.
“As the trial continues to progress, we are delighted to observe the continuation of our robust safety record, as Lupuzor is being administered to greater numbers of patients over a longer period of time,” chairman Tim McCarthy said
Big potential market
Systemic Lupus Erythematosus (SLE) is a debilitating and painful disease, which sees the body's immune system turn against itself for reasons still not fully understood.
It can affect various organs in various people in various ways so many symptoms can ensue, which calls for treatment from heart, liver and skin specialists.
It is much more common in women, appears most often in African-Americans, Asians and Hispanics and it is estimated that up to five million individuals worldwide may be affected.
ImmuPharma does not claim Lupuzor is a cure but hopes it will offer significant relief to sufferers such that their quality of life is greatly improved.